<DOC>
	<DOCNO>NCT00551564</DOCNO>
	<brief_summary>Insulin resistance ( IR ) common many metabolic disorder predispose individual Type 2 Diabetes Mellitus ( T2DM ) , Metabolic Syndrome coronary atherosclerosis . Non-diabetics IR risk , difficult diagnose . A major problem use IR predictor marker disease lack simple , robust test use quantify parameter wide variety clinical situation . The current 'gold standard ' method measure insulin sensitivity , hyperinsulinemic-euglycemic ( H-E ) clamp , complex , time consume costly . Alternative , simple method , Homeostasis Model Assessment ( HOMA-IR ) score , may less accurate widely accept .</brief_summary>
	<brief_title>Study Determine Utility Novel Technologies Biomarkers Measure Human Response Rosiglitazone Maleate</brief_title>
	<detailed_description>A Single-Center , Non-Randomized , Open-Label , Comparative Study Assess Utility Novel Technologies Biomarkers Methods Measuring Human Pharmacodynamic Response 8 Weeks Administration Rosiglitazone Maleate 4mg BID Healthy Normal Overweight Controls , Healthy Obese Subjects Subjects Type 2 Diabetes Mellitus ( T2DM ) .</detailed_description>
	<mesh_term>Diabetes Mellitus</mesh_term>
	<mesh_term>Diabetes Mellitus , Type 2</mesh_term>
	<mesh_term>Rosiglitazone</mesh_term>
	<mesh_term>Maleic acid</mesh_term>
	<criteria>Male and/or female age 1865 year Females must either nonchildbearing potential childbearing potential ( pregnant ) use appropriate method contraception . Healthy normal overweight control subject healthy obese subject subject T2DM . Clinically significant past current medical condition Clinically significant abnormality vital sign routine laboratory parameter</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>65 Years</maximum_age>
	<verification_date>October 2016</verification_date>
	<keyword>total body water</keyword>
	<keyword>T2DM ,</keyword>
	<keyword>Healthy Obese ,</keyword>
	<keyword>Insulin Resistance ,</keyword>
	<keyword>Rosiglitazone maleate ,</keyword>
	<keyword>Glucose Disposal ,</keyword>
	<keyword>hyperinsulinemic-euglycemic clamp ,</keyword>
</DOC>